← Back to Clinical Trials
Recruiting NCT07009886

NCT07009886 Development of an Educational Patient Decision Aid (Treatments in Advanced Cancer - Decision Aid, TA-DA) to Promote Shared Decision Making for Third-line or Beyond Palliative Systemic Therapy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07009886
Status Recruiting
Phase
Sponsor M.D. Anderson Cancer Center
Condition Advanced Cancer
Study Type INTERVENTIONAL
Enrollment 155 participants
Start Date 2025-07-10
Primary Completion 2028-07-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Communication

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 155 participants in total. It began in 2025-07-10 with a primary completion date of 2028-07-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

To develop an educational patient decision aid for advanced cancer patients to prepare them to have conversations with their clinicians about treatment options (Treatments in Advanced cancer - Decision Aid, TA-DA).

Eligibility Criteria

Inclusion Criteria: 1. Clinicians (Part I/II/III): MD Anderson medical oncologists and APPs who provide care to patients with advanced cancer 2. Patients (Part I/II/III): Age 18 or over * Diagnosis of advanced cancer (i.e., metastatic, relapsed, and/or incurable disease as defined by the treating oncologist) who has received at least 2 lines of palliative systemic therapy\* * Patient-rated ECOG performance status of 1-3 for Part I/II and 2-3 for Part III * Able to make treatment decisions based on the clinical judgement of the oncology team * English speaking * patient has started, is receiving, and/or has completed second-line palliative systemic therapy or beyond 3. Caregivers (Part I/II/III): * Age 18 or older * Currently a primary caregiver to a patient who satisfies the patient eligibility criteria listed above * For the study purposes, a primary caregiver is defined as: * someone who provides physical, emotional, decisional and/or logistical assistance to the patient regularly (e.g. daily, weekly); * can be a family member, friend, or other individual in a close relationship with the patient; * must be identified by the patient and self-identify as the primary person providing caregiving support to the patient * Able to provide informed consent and participate in the study * English speaking Exclusion Criteria: Any patient who meets any of the following criteria will be excluded from participation in this study: * (Part I/II/III): Diagnosis of cognitive impairment or dementia requiring a surrogate decision maker as determined by the clinical team * (Part III only): Participants in Part I and II

Contact & Investigator

Central Contact

David Hui, MD

✉ dhui@mdanderson.org

📞 (713) 792-6258

Principal Investigator

David Hui, MD

PRINCIPAL INVESTIGATOR

M.D. Anderson Cancer Center

Frequently Asked Questions

Who can join the NCT07009886 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Advanced Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07009886 currently recruiting?

Yes, NCT07009886 is actively recruiting participants. Contact the research team at dhui@mdanderson.org for enrollment information.

Where is the NCT07009886 trial being conducted?

This trial is being conducted at Houston, United States.

Who is sponsoring the NCT07009886 clinical trial?

NCT07009886 is sponsored by M.D. Anderson Cancer Center. The principal investigator is David Hui, MD at M.D. Anderson Cancer Center. The trial plans to enroll 155 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology